Sugi Predict

Sugi Predict / Compounds / SCHEMBL156133

SCHEMBL156133

SCHEMBL156133

CC(C)(C)OC(=O)N1C2CCCC1CC(=O)C2

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.56
▸ CHRM1 P11229 1/20 0.56
▸ CHRM3 P20309 1/20 0.56
▸ MAPK1 P28482 1/20 0.48
▸ PREP P48147 4/20 0.46
▸ HSD11B1 P28845 1/20 0.43
▸ KAT2B Q92831 1/20 0.42
▸ HPGD P15428 1/20 0.40
▸ SPR P35270 2/20 0.39
▸ EPHX1 P07099 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ KMT2A Q03164 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ HCAR1 Q9BXC0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12875999 1.00 CHRM2 (0.56) CHRM2CHRM1CHRM3MAPK1PREP
SCHEMBL13931011 0.93 CHRM2 (0.64) CHRM2CHRM1CHRM3MAPK1PREP
SCHEMBL722238 0.93 CHRM2 (0.64) CHRM2CHRM1CHRM3MAPK1PREP
SCHEMBL23658362 0.93 CHRM2 (0.64) CHRM2CHRM1CHRM3MAPK1PREP
SCHEMBL413300 0.93 CHRM2 (0.64) CHRM2CHRM1CHRM3MAPK1PREP
SCHEMBL23658364 0.93 CHRM2 (0.64) CHRM2CHRM1CHRM3MAPK1PREP
SCHEMBL14545684 0.87 CHRM2 (0.65) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL12461664 0.87 CHRM2 (0.65) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL2813407 0.86 CHRM2 (0.59) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL20635190 0.85 CHRM2 (0.68) CHRM2CHRM1CHRM3PREPHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114315820-A Preparation method of N-Boc-9-azabicyclo [3.3.1] nonane-3-ketone 安徽益多康尔医药科技有限公司 2022-04-12 — — CN claimed
US-12617783-B2 Heterocyclic GLP-1R agonists BIOMEA FUSION, INC. (US) 2026-05-05 — — US disclosed
US-12612397-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2026-04-28 — — US disclosed
US-12522597-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2026-01-13 — — US disclosed
US-12509460-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2025-12-30 — — US disclosed
US-20250339411-A1 GLP-1R AGONIST COMPOUND AND USE THEREOF CHONGQING PHARMACEUTICAL RES INSTITUTE CO LTD (CN) 2025-11-06 — — US disclosed
EP-3638658-B1 PHARMACEUTICAL COMPOUNDS NXERA PHARMA UK LTD (GB) 2025-10-08 — — EP disclosed
US-20250304572-A1 HETEROCYCLIC GLP-1R AGONISTS BIOMEA FUSION, INC. 2025-10-02 — — US disclosed
US-12419874-B2 GLP-1R agonist compound and use thereof CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) 2025-09-23 — — US disclosed
US-20250243171-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE ARTHROSI THERAPEUTICS, INC. 2025-07-31 — — US disclosed
EP-1861099-A2 COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN Novartis AG (CH) 2007-12-05 — — EP disclosed
EP-1861098-A1 ANTI-INFLAMMATORY COMPOUNDS Novartis AG (CH) 2007-12-05 — — EP disclosed
US-20070049612-A1 Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2007-03-01 — — US disclosed
WO-2006097293-A2 COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN NOVARTIS AG (CH) 2006-09-21 — — WO disclosed
WO-2006097292-A1 ANTI-INFLAMMATORY COMPOUNDS NOVARTIS AG (CH) 2006-09-21 — — WO disclosed
WO-2006092268-A1 BICYCLIC FIVE-MEMBERED HETEROARYL DERIVATIVES AND THEIR USE AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2006-09-08 — — WO disclosed
WO-2006021403-A1 BICYCLONONENE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2006-03-02 — — WO disclosed
US-20050059712-A1 Acylsulfonamides as inhibitors of steroid sulfatase NOVARTIS AG (CH) 2005-03-17 — — US disclosed
EP-1436253-A1 ACYLSULFONAMIDES AS INHIBITORS OF STEROID SULFATASE Novartis AG (CH) 2004-07-14 — — EP disclosed
WO-2003031397-A1 ACYLSULFONAMIDES AS INHIBITORS OF STEROID SULFATASE NOVARTIS AG (CH) 2003-04-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304572-A1 HETEROCYCLIC GLP-1R AGONISTS GLP1R, GPR119, GIPR CHRM2 1677/4885CHRM1 1928/4885CHRM3 589/4885
US-12617783-B2 Heterocyclic GLP-1R agonists GLP1R, GIPR, GPR119 CHRM2 402/4885CHRM1 353/4885CHRM3 352/4885
US-12509460-B2 Methods and compositions for modulating splicing SF3B1, RTCB, RBM17 CHRM2 4220/4885CHRM1 3901/4885CHRM3 4010/4885
US-12612397-B2 Methods and compositions for modulating splicing SF3B1, SF3B2, SF1 CHRM2 3821/4885CHRM1 3301/4885CHRM3 3398/4885
US-20250243171-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE EGFR, ABL1, ERBB2 CHRM2 4840/4885CHRM1 4813/4885CHRM3 4711/4885
US-20250339411-A1 GLP-1R AGONIST COMPOUND AND USE THEREOF GLP1R, GIPR, GPR119 CHRM2 1771/4885CHRM1 1032/4885CHRM3 926/4885
US-20050059712-A1 Acylsulfonamides as inhibitors of steroid sulfatase STS, SULT2A1, ARSA CHRM2 2442/4885CHRM1 2531/4885CHRM3 2378/4885
US-12419874-B2 GLP-1R agonist compound and use thereof GLP1R, GIPR, GPR119 CHRM2 1771/4885CHRM1 1032/4885CHRM3 926/4885
US-20070049612-A1 Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase BACE1, BACE2, PSEN1 CHRM2 656/4885CHRM1 515/4885CHRM3 785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.